Zorecimeran
Highest phase reached
Phase 3
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Oligonucleotide
- Drug name
- Zorecimeran
- curevac mrna based vaccine immunogen candidate against covid 19
- CUREVAC MRNA-BASED VACCINE IMMUNOGEN CANDIDATE AGAINST COVID-19
- cv 07050101
- CV-07050101
- cv07050101
- CV07050101
- cvncov
- Cvncov
- CVnCoV
- CVNCOV
- cvncov 12 μg
- CVnCoV 12 μg
- cvncov 12μg
- CVnCoV 12μg
- cvncov 6 μg
- CVnCoV 6 μg
- MESSENGER RNA (MRNA), 5'-CAPPED, ENCODING A FULL-LENGTH CODON-OPTIMISED PRE-FUSION STABILIZED CONFORMATION VARIANT (K986P AND V987P) OF THE SARS-COV-2 (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; NC_045512.2) SPIKE (S) GLYCOPROTEIN, FLANKED BY 5' AND 3' UNTRANSLATED REGIONS; THE 3' UNTRANSLATED REGION COMPRISES A PART OF THE HUMAN ALPHA GLOBIN GENE 3' UTR SEQUENCE ELEMENT, A SYNTHETIC POLY(A) TAIL AND A POLY(C)-RICH SEQUENCE FOLLOWED BY A HISTONE STEM LOOP SEQUENCE AS A 3' TAIL. IMMUNOLOGICAL AGENT FOR ACTIVE IMMUNIZATION (ANTI-SARS-COV-2)
- messenger rna mrna 5 capped encoding a full length codon optimised pre fusion stabilized conformation variant k986p and v987p of the sars cov 2 severe acute respiratory syndrome coronavirus 2 nc 045512 2 spike s glycoprotein flanked by 5 and 3 untranslated regions the 3 untranslated region comprises a part of the human alpha globin gene 3 utr sequence element a synthetic poly a tail and a poly c rich sequence followed by a histone stem loop sequence as a 3 tail immunological agent for active immunization anti sars cov 2
- RNA (RECOMBINANT 5'-(M7G-(5'->5')-PPP-AM)-CAPPED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 PRE-FUSION SPIKE GLYCOPROTEIN (986-PROLINE,987-PROLINE)-SPECIFYING 3'-TAILED MESSENGER R9515), INNER SALT
- rna recombinant 5 m7g 5 5 ppp am capped severe acute respiratory syndrome coronavirus 2 pre fusion spike glycoprotein 986 proline 987 proline specifying 3 tailed messenger r9515 inner salt
- sars cov 2 mrna vaccine cvncov
- SARS-CoV-2 mRNA Vaccine (CVnCoV)
- zorecimeran
- Zorecimeran
- zorecimeran [INN]
And 3 more, listed on the interactive page.
- CAS registry numbers
- 2432957-15-6
- ChEMBL ID
- CHEMBL4802204
- FDA ingredient codes (UNII)
- 5TP24STD1S
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -meran
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000694
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT04449276
- NCT04652102
- NCT04674189
- NCT04838847
- NCT04860258
- NCT04848467
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (10)
- A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
- A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
- A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
- A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
- A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19
- A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
- COVID-19 Vaccines Safety Tracking (CoVaST)
- COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities
- COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older
- Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
In development for (2)
- COVID-19 Phase 3
- Severe acute respiratory syndrome Phase 3